Literature DB >> 19130415

Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.

Mevlüt Koç1, Abdi Bozkurt, Durmus Yildiray-Sahin, Ilker Unal, Esmeray Acartürk.   

Abstract

BACKGROUND: It has been demonstrated in numerous studies that N-terminal pro-B-type natriuretic peptide (NT-proBNP) is strongly associated with left ventricular ejection fraction (LVEF), functional capacity (FC), and cardiovascular (CV) mortality in heart failure (HF) patients. The aim of the present study was to determine the predictive cutoff values of NT-proBNP for predicting these parameters.
METHODS: One hundred HF patients (88 male, 12 female, mean age 53.6 +/- 8.9 years) with left ventricular (LV) systolic dysfunction and impaired exercise capacity were enrolled into the study. Echocardiographic examination was performed. The NT-proBNP concentration was measured after resting for 20 min in the supine position. The modified Bruce protocol was utilized for exercise testing. The patients were followed for between 690 and 840 days (mean 750 +/- 30 days) for the occurrence of CV events.
RESULTS: There was a strong negative correlation between NT-proBNP concentration and LVEF (p < 0.004). It was found that NT-proBNP is a strong predictor of LVEF < 30% (p < 0.001). When 940 pg/mL was accepted as a cutoff value for NT-proBNP for the prediction of an LVEF < 30%, the sensitivity and the specificity were 89.8% and 71.4%, respectively. NT-proBNP and left atrial diastolic dimension were the most significant parameters for predicting FC (p < 0.001, each one). An NT-proBNP cutoff value of 940 pg/mL responded to 78.8% sensitivity and 81% specificity for the prediction of FC < 5 METs. The observed independent predictors for the CV events were NT-proBNP, LV mass index, and resting heart rate (p < 0.001, p = 0.02 and p = 0.006, respectively). Every 1000 pg/mL elevation in NT-proBNP level resulted in a 27% increase in the occurrence of CV events (p < 0.006). Moreover, 940 pg/mL NT-proBNP cutoff value revealed a sensitivity and specificity of 86.7% and 64.7% respectively for the prediction of incident CV events.
CONCLUSIONS: Use of NT-proBNP cutoff values is easy and reliable method for the prediction of low FC and decreased LVEF, and may aid identification of patients at the highest risk for future CV events. We suggest to use NT-proBNP cutoff value of 940 pg/mL for predicting these parameters.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19130415

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  6 in total

1.  Non-invasive pressure support ventilation and CPAP in cardiogenic pulmonary edema: a multicenter randomized study in the emergency department.

Authors:  Semir Nouira; Riadh Boukef; Wahid Bouida; Wieme Kerkeni; Kaouther Beltaief; Hamdi Boubaker; Latifa Boudhib; Mohamed Habib Grissa; Mohamed Naceur Trimech; Hamadi Boussarsar; Mehdi Methamem; Soudani Marghli; Mondher Ltaief
Journal:  Intensive Care Med       Date:  2010-12-07       Impact factor: 17.440

Review 2.  BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure.

Authors:  Mark Oremus; Andrew Don-Wauchope; Robert McKelvie; Pasqualina L Santaguida; Stephen Hill; Cynthia Balion; Ronald Booth; Judy A Brown; Usman Ali; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

3.  Limited usefulness of resting hemodynamic assessments in predicting exercise capacity in hypertensive patients.

Authors:  Małgorzata Kurpaska; Paweł Krzesiński; Grzegorz Gielerak; Beata Uziębło-Życzkowska
Journal:  J Hum Hypertens       Date:  2020-06-25       Impact factor: 3.012

4.  Serum glutathione S-transferase P1 1 in prediction of cardiac function.

Authors:  Olena Andrukhova; Mohamed Salama; Raphael Rosenhek; Matthias Gmeiner; Thomas Perkmann; Johannes Steindl; Seyedhossein Aharinejad
Journal:  J Card Fail       Date:  2011-12-20       Impact factor: 5.712

5.  Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study.

Authors:  Devine S Frundi; Eva Kettig; Lena Luise Popp; Melanie Hoffman; Marine Dumartin; Magali Hughes; Edgar Lamy; Yvonne Joko Walburga Fru; Arjola Bano; Taulant Muka; Matthias Wilhelm
Journal:  Front Cardiovasc Med       Date:  2022-07-22

6.  Diagnostic Values of Plasma, Fresh and Frozen Urine NT-proBNP in Heart Failure Patients.

Authors:  Mehrnoush Toufan; Hossein Namdar; Mohsen Abbasnezhad; Afshin Habibzadeh; Heidarali Esmaeili; Saeid Yaraghi; Zhila Samani
Journal:  J Cardiovasc Thorac Res       Date:  2014-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.